Home Alzheimer’s Disease Belantamab Mafodotin Shows Promising Response in Relapsed/Refractory Multiple Myeloma

Belantamab Mafodotin Shows Promising Response in Relapsed/Refractory Multiple Myeloma

Belantamab mafodotin monotherapy induced durable responses and appeared to be well tolerated  in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM), according to updated findings from the phase 2 DREAMM-2 trial presented as part of the 2020 ASCO Virtual Scientific Program.

In a 13-month follow-up analysis, the overall response rate (ORR) was 32% (31/97; 97.5% CI, 21.7%-43.6%) for patients treated in the 2.5-mg/kg cohort and 35% (35/99; 97.5% CI, 23.9%-46.0%) in the 3.4-mg/kg cohort.

The duration of response (DoR) was not reached (NR) in either cohort. The median DoR estimate was 11.0 months (95% CI, 4.2-NR) and 6.2 months (95% CI, 4.8-NR), respectively. Further, more than half of patients who achieved a response in both cohorts, had a very good partial response (VGPR) or better (58% and 66%, respectively).1

The VGPR analyses included 11 patients with VGPR,…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

My Brain Tumor Taught Me To Shift My Perspective on These 5 Things

submitted by /u/andrewjoegeorge Continue Reading to the Source

Recent Comments